The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure
Abdul Al-Hesayen, MD*,
Eduardo R. Azevedo, MD*,
Gary E. Newton, MD* and
John D. Parker, MD, FACC*,*
* Division of Cardiology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Canada

View larger version (19K):
[in a new window]
|
Figure 1 Cardiac norepinephrine spillover rate (CANESP) with dobutamine in the congestive heart failure (CHF) group versus the normal left ventricular (LV) function group. Solid triangle = normal LV on no beta-blocker; open triangle = normal LV on beta-blocker; open circle = CHF on no beta-blocker; solid circle = CHF on beta-blocker. C = control; Dob = Dobutamine. *p < 0.05 vs. control; p < 0.05 response in CHF group versus response in normal LV group.
|
|
|